May 26, 2022

This week, Dr. Mikhail Kosiborod, cardiologist at Saint Luke’s Mid America Heart Institute and Vice President of Research at Saint Luke's Health System, presented two Late-Breaking Science Submissions at the European Society of Cardiology Heart Failure Congress in Madrid, Spain.

TCTMD talked to Dr. Kosiborod about his presentations on the DEFINE-HF and PRESERVED-HF trials.

Watch the full TCTMD interview: Beyond the Data: DEFINE-HF and PRESERVED-HF

Related Content

TCTMD: Dapagliflozin Boosts Health Status Across LVEF Range
Dapagliflozin improves symptoms and physical limitations in people with heart failure across the spectrum of ejection fractions, according to a pooled analysis of the DEFINE-HF and PRESERVED-HF trials.
American Heart Association News: Black, Hispanic Adults Less Likely to Receive CPR, Especially in Public
Black or Hispanic adults who experience a witnessed cardiac arrest outside the hospital are substantially less likely than their white peers to receive lifesaving care from a bystander, preliminary new research shows.
touchCardio: Mikhail Kosiborod, ACC 2022: Results from the EMPULSE Trial
touchCARDIO spoke with Dr. Mikhail Kosiborod to discuss his presentation on the EMPULSE trial and the impact of SGLT-2 inhibitors and where they sit in the future treatment paradigm for heart failure.